Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 35.e15-35.e19

  Lightfoot, Andrew J ^a   Breyer, Benjamin N ^b   Rosevear, Henry M ^a   Erickson, Bradley A ^a   Konety, Badrinath R ^c   O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antineoplastic therapy; Bladder cancer; Chemotherapy protocols; Gemcitabine; Mitomycin

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; GEMCITABINE; MITOMYCIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CLINICAL ARTICLE; CYSTECTOMY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PERICARDITIS; PRIORITY JOURNAL; RASH; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; URGE INCONTINENCE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTECTOMY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84890786394     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.01.009     Document Type: Article

References (23)

1. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124-1129.
2. Hussain M.H., Wood D.P., Bajorin D.F., et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 2009, 27:5680-5684.
3. van der Meijden A.P., Sylvester R., Oosterlinck W., et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005, 48:363-371.
4. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Bohle A., Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314.
5. Hall M.C., Chang S.S., Dalbagni G. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178:2314-2330.
6. Lightfoot A.J., Rosevear H.M., O'Donnell M.A. Recognition and treatment of BCG failure in bladder cancer. Sci World J 2011, 11:602-613.
7. Fukui I., Sekine H., Kihara K. Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder. J Urol 1989, 141:531-534.
8. Maymí J.L., Saltsgaver N., O'Donnell M.A. Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer. J Urol 2006, 175(Suppl. 4):271. [abstract no. 840].
9. Breyer B.N., Whitson J.M., Carroll P.R., Konety B.R. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 2010, 28:510-514.
10. Wientjes M.G., Badalament R.A., Au J.L. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 1993, 32:255-262.
11. Grossman H.B., O'Donnell M.A., Cookson M.S., Greenberg R.E., Keane T.E. Bacillus calmette-guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol 2008, 10:281-289.
12. National Cancer Institute (U.S.) Common terminology criteria for adverse events (CTCAE) 2009, U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD. Rev. ed.
13. Malmstrom P.U., Wijkstrom H., Lundholm C., Wester K., Busch C., Norlen B.J. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999, 161:1124-1127.
14. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003, 170:777-782.
15. van der Heijden A.G., Kiemeney L.A., Gofrit O.N., et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004, 46:65-72.
16. Gofrit O.N., Shapiro A., Pode D., et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004, 63:466-471.
17. Mohanty N.K., Nayak R.L., Vasudeva P., Arora R.P. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol 2008, 26:616-619.
18. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006, 24:2729-2734.
19. Bartoletti R., Cai T., Gacci M., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 2005, 66:726-731.
20. Sylvester R.J., Brausi M.A., Kirkels W.J., et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010, 57:766-773.
21. Oosterlinck W., Kirkali Z., Sylvester R., et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol 2011, 59:438-446.
22. Moibi J.A., Mak A.L., Sun B., Moore R.B. Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL. Int J Oncol 2011, 39:61-71.
23. Cho D.Y., Bae J.H., Moon D.G., et al. The effects of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guerin in superficial bladder cancer: a preliminary study. J Int Med Res 2009, 37:1823-1830.